Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
This was the stock's second consecutive day of losses.
InsideNoVa (English) on MSN2h
Colgan High School senior named finalist in prestigious science and math competitionA Colgan High School senior was named one of the top 40 finalists in the 2025 Regeneron Science Talent Search, a prestigious ...
Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...
Hosted on MSN3h
Stocks Recover Early Losses as Chip Stocks RallyThe S&P 500 Index ($SPX) (SPY) today is down -0.02%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.06%, and the ...
The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...
Hosted on MSN8hOpinion
Very Important Patients Don't Just Do Something, Stand There!What lessons can be learnt from treating Trump? Why is his proclamation of Regeneron's unproven and experimental antibody ...
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in ...
Federal agencies have removed web pages dedicated to DEI programs related to cancer research and other clinical research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback